Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CG 428 for Chemotherapy-Induced Alopecia
NCT02919735Phase 2Completed
- Sponsor
- Legacy Healthcare
- Start
- Oct 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chemotherapy-induced alopecia (CIA) comparing CG 428 with Placebo (2 arms). Primary endpoint: Rate of hair loss based on Olsen's Visual Analog Scale (OVAS) and Severity of Alopecia Tool (SALT). Started Oct 2016; status: completed.
02
Drugs
CG 428
03
Conditions
Chemotherapy-induced alopecia (CIA)
Beyond the preview
Go deeper on NCT02919735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919735.